Major impact from early use of abiraterone + ADT in metastatic disease

The abstracts of the LATITUDE trial and the comparable arm of the STAMPEDE trial, in which patients with newly diagnosed, metastatic prostate cancer were randomized to either ADT or ADT + abiraterone acetate + prednisone were both released this morning. Both trials have shown major benefits to the early addition of abiraterone acetate to standard care. We shall be providing more details in separate reports to come later today.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: